Shire Continues to Deliver Excellent Growth From Cor...(123 156 279 Net income/(lo...),Health

Date:10/30/2009

123 156 279 Net income/(loss) 60 29 89 (35) 251 216 Diluted earnings /(loss) per ADS 33c 16c 49c (20c) 137c 117c Note: Average exchange rates for Q3 2009 were $1.64:GBP1.00 and $1.43:EUR1.00, (Q3 2008: $1.89:GBP1.00 and $1.52:EUR1.00). (1) The Non GAAP financial measures included above are explained on pages 26 and 27, together with an explanation of why Shire's management believes that these measures are useful to investors. For a reconciliation of these Non GAAP financial measures to the most directly comparable financial measures prepared in accordance with US GAAP, see pages 22 to 25. FINANCIAL SUMMARY Third Quarter 2009 (see page 7 for full Financial Results) - Product sales from core products were up 20% (up 23% at CER) to $532 million, driven by continued strong growth from: - VYVANSE(R) (up 34% to $129 million); - LIALDA(R)/MEZAVANT(R) (up 62% to $65 million); - ELAPRASE(R) (up 16% to $91 million, up 20% at CER); and - REPLAGAL(R) (up 8% to $48 million, up 15% at CER). - Product sales including ADDERALL(R) XR, were down 15% to $603 million, as ADDERALL XR product sales declined by 74%, or $198 million to $71 million. - Non GAAP operating income decreased by 52%, or $145 million, to $134 million due to the lower ADDERALL XR revenues in Q3 2009 and increased investment in research and development, which were partially offset by higher revenues from core products and lower selling, general and administrative costs. On a US GAAP basis operating income in Q3 2009 was $92 million, compared to $123 million in 2008 (2008 included the impact of a $121 million in-process R&D charge relating to the acquisition of Jerini AG ("Jerini")). - Non GAAP diluted earnings per ADS were down 58% to $0.49 (Q3 2008: $1.
'/>"/>

SOURCE Shire Plc Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33
Related medicine technology :

1. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
2. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
3. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
5. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
6. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
7. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
8. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
9. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
10. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease